Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors

被引:41
|
作者
Yao, Zhangyu [1 ]
Wei, Xueying [1 ]
Wu, Xiaoming [1 ]
Katz, Jonathan L. [2 ]
Kopajtic, Theresa [2 ]
Greig, Nigel H. [3 ]
Sun, Hongbin [1 ]
机构
[1] China Pharmaceut Univ, Coll Pharm, Ctr Drug Discovery, Nanjing 210009, Peoples R China
[2] Natl Inst Drug Abuse, Psychobiol Sect, Intramural Res Program, NIH, Baltimore, MD 21224 USA
[3] NIA, Drug Design & Dev Sect, Lab Neurosci, Intramural Res Program,NIH, Baltimore, MD 21224 USA
关键词
Tetrabenazine enantiomers; Dihydrotetrabenazine stereoisomers; Resolution; Huntington's chorea; VMAT2; Hyperkinetic disorders; MONOAMINE TRANSPORTER; MOVEMENT-DISORDERS; METABOLITE; EPOXIDES; EMETINE; BINDING; DRUGS;
D O I
10.1016/j.ejmech.2011.02.046
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Tetrabenazine (TBZ) ((+/-)-1) and dihydrotetrabenazines (DHTBZ) are potent inhibitors of VMAT2. Herein, a practical chemical resolution of (+/-)-1 and stereoselective synthesis of all eight DHTBZ stereoisomers are described. The result of VMAT2 binding assay revealed that (+)-1 (K-i = 4.47 nM) was 8000-fold more potent than ()-1 (K-i = 36,400 nM). Among all eight DHTBZ stereoisomers, (2R,3R,11bR)-DHTBZ ((+)-2: K-i= 3.96 nM) showed the greatest affinity for VMAT2. The (3R,11bR)-configuration appeared to play a key role for VMAT2 binding. In summary, (+)-1, (+)-2, and their derivatives warrant further studies in order to develop more potent and safer drugs for the treatment of chorea associated with Huntington's disease and other hyperkinetic disorders. (C) 2011 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:1841 / 1848
页数:8
相关论文
共 10 条
  • [1] Preparation and Characterization of Tetrabenazine Enantiomers against Vesicular Monoamine Transporter 2
    Yu, Qian-sheng
    Luo, Weiming
    Deschamps, Jeffery
    Holloway, Harold W.
    Kopajtic, Theresa
    Katz, Jonathan L.
    Brossi, Arnold
    Greig, Nigel H.
    ACS MEDICINAL CHEMISTRY LETTERS, 2010, 1 (03): : 105 - 109
  • [2] VMAT2 inhibitors for the treatment of tardive dyskinesia
    Scorr, Laura M.
    Factor, Stewart A.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2018, 389 : 43 - 47
  • [3] Synthesis and biological evaluation of 3-alkyl-dihydrotetrabenazine derivatives as vesicular monoamine transporter-2 (VMAT2) ligands
    Zheng, Pinguan
    Lieberman, Brian P.
    Choi, Seok Rye
    Ploeessl, Karl
    Kung, Hank F.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (11) : 3435 - 3438
  • [4] (+)-9-Benzyloxy-α-Dihydrotetrabenazine as an Important Intermediate for the VMAT2 Imaging Agents: Absolute Configuration and Chiral Recognition
    Liu, Chunyi
    Chen, Zhengping
    Li, Xiaomin
    Tang, Jie
    Qin, Xiaofeng
    CHIRALITY, 2013, 25 (04) : 215 - 223
  • [5] Structural requirement of C11b chirality of tetrabenazine analogs as VMAT2 imaging ligands: synthesis and in vivo evaluation
    Xue, Danlu
    Liu, Chunyi
    Li, Xiaomin
    Tang, Jie
    Cao, Lihua
    Liu, Yi
    Chen, Zhengping
    JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, 2017, 313 (02) : 419 - 428
  • [6] 9-Cyclopropylmethoxy-dihydrotetrabenazine and its stereoisomers as vesicular monoamine transporter-2 inhibitors
    Wang, Wenyan
    Lin, Shilan
    Du, Guangying
    Bai, Xinfa
    Lu, Jing
    Ye, Liang
    Wang, Hongbo
    Zhang, Rui
    Tian, Jingwei
    FUTURE MEDICINAL CHEMISTRY, 2022, 14 (13) : 991 - 1003
  • [7] Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review
    Golsorkhi, Mohadese
    Koch, Jessa
    Pedouim, Farzin
    Frei, Karen
    Bondariyan, Niloofar
    Dashtipour, Khashayar
    TREMOR AND OTHER HYPERKINETIC MOVEMENTS, 2024, 14 : 1 - 12
  • [8] Deuterated 18F-9-O-hexadeutero-3-fluoropropoxyl-(+)dihydrotetrabenazine (D6-FP-(+)-DTBZ): A vesicular monoamine transporter 2 (VMAT2) imaging agent
    Liu, Futao
    Choi, Seok Rye
    Zha, Zhihao
    Ploessl, Karl
    Zhu, Lin
    Kung, Hank F.
    NUCLEAR MEDICINE AND BIOLOGY, 2018, 57 : 42 - 49
  • [9] Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivo
    Meyer, Andrew C.
    Neugebauer, Nichole M.
    Zheng, Guangrong
    Crooks, Peter A.
    Dwoskin, Linda P.
    Bardo, Michael T.
    JOURNAL OF NEUROCHEMISTRY, 2013, 127 (02) : 187 - 198
  • [10] Risk of VMAT2 inhibitors on suicidality and parkinsonism: report utilizing the United States Food and Drug Administration adverse event reporting system
    Wong, Sabrina
    Le, Gia Han
    Kwan, Angela T. H.
    Rhee, Taeho Greg
    Teopiz, Kayla M.
    Ho, Roger C.
    Cao, Bing
    Rosenblat, Joshua D.
    Mansur, Rodrigo
    Mcintyre, Roger S.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2025, 40 (03) : 176 - 181